Lv5
1020 积分 2026-04-21 加入
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
18天前
已完结
Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis
1个月前
已完结
Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti–Tissue Factor Pathway Inhibitor Antibody, PF-06741086
2个月前
已完结
Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis
2个月前
已关闭
Isatuximab Plus Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus Vrd in Chinese Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant: IMROZ Subgroup Analysis
2个月前
已关闭
Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
2个月前
已完结
Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention
2个月前
已完结
Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma
2个月前
已完结
Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma
2个月前
已完结
Safety and efficacy of marstacimab in patients with hemophilia A and B: a systematic review and meta-analysis
2个月前
已完结
皖公网安备34019202002308
